CLAIMS

1. A pharmaceutical composition comprising a LABA agent, a LAMA agent, a co-solvent, a propellant and a mixture of an acid and a chelating agent.

2. The pharmaceutical composition according to claim 1 wherein the LABA agent is selected from the group consisting of: fenoterol, formoterol fumarate, formoterol fumarate dihydrate, arformoterol, carmoterol (TA-2005), indacaterol, milveterol, bambuterol, clenbuterol, vilanterol, olodaterol, abediterol, terbutaline, salmeterol, diastereoisomeric mixtures, and a pharmaceutically acceptable salt thereof or hydrate thereof.

3. The pharmaceutical composition according to claim 2, wherein the LABA agent is formoterol fumarate.

4. The pharmaceutical composition according to claim 3, wherein the LABA agent is formoterol fumarate dihydrate.

5. The pharmaceutical composition according to any claims 1 to 4, further comprising a LAMA agent selected from the group consisting of: glycopyrronium, ipratropium, oxitropium, trospium, tiotropium, aclidinium and umeclidinium with any pharmaceutically counterion thereof.

6. The pharmaceutical composition according to claim 5, wherein the LAMA agent is glycopyrronium bromide.

7. The pharmaceutical composition according to any claims 1 to 6, wherein the acid is selected from an inorganic acid, an organic acid or a mixture thereof.

8. The pharmaceutical composition according to claim 7 wherein the acid is HCl.

9. The pharmaceutical composition according to any claims 1 to 9, wherein the chelating agent is selected from EDTA, $EDTANa_2$, $EDTANa_2Ca$, EDTACa, preferably $EDTANa_4$.

10. The pharmaceutical composition according to any claims 1 to 10, wherein said mixture of an acid and a chelating agent is a mixture of HCl and $EDTANa_4$.

11. The pharmaceutical composition according to any claims 1 to 10, further comprising a corticosteroid selected form the group consisting of: budesonide, beclometasone (BDP), e.g. as the mono or the dipropionate ester, flunisolide, fluticasone, e.g. as the propionate or

furoate ester, ciclesonide, mometasone, e.g. as the furoate ester, mometasone desonide, rofleponide, hydrocortisone, prednisone, prednisolone, methyl prednisolone, naflocort, deflazacort, halopredone acetate, fluocinolone acetonide, fluocinonide, clocortolone, tipredane, prednicarbate, alclometasone dipropionate, halometasone, rimexolone, deprodone propionate, triamcinolone, betamethasone, fludrocoritisone, desoxycorticosterone, rofleponide, etiprednol dicloacetate.

12. The pharmaceutical composition according to claim 11, wherein the corticosteroid is budesonide or beclometasone dipropionate (BDP).

13. The pharmaceutical composition according to any claims 1 to 12, wherein the co-solvent is an aliphatic alcohol having from 1 to 4 carbon atoms.

14. The pharmaceutical composition according to any claims 1 to 13, wherein the propellant is selected from: hydrofluoroalkanes (HFAs) and hydrofluoroolefins (HFOs) and mixture thereof.

15. The pharmaceutical composition according to claim 14, wherein the propellant is selected from: HFA134a, HFA152a and mixtures thereof.

16. The pharmaceutical composition according to any claims 1 to 15, wherein the LABA agent is formoterol fumarate dihydrate, the corticosteroid is beclometasone dipropionate (BDP), the LAMA agent is glycopyrronium bromide, the propellant is HFA134a, the inorganic acid is HCl, the chelating agent is $EDTANa_2$, the co-solvent is ethanol, and the composition is a solution.

17. The pharmaceutical composition according to any claims 1 to 15, wherein the LABA agent is formoterol fumarate dihydrate, the corticosteroid is budesonide or beclometasone dipropionate (BDP), the LAMA agent is glycopyrronium bromide, the propellant is HFA152a, the inorganic acid is HCl, the chelating agent is EDTANa2, the co-solvent is ethanol and the composition is a solution.

18. A canister containing the pharmaceutical composition according to any claims 1 to 17, wherein the canister is made of aluminum, stainless steel, anodized aluminum and fluorine passivated aluminum.

19. Use of the pharmaceutical composition according to claim 17 in the manufacture of a medicament for the treatment and/or prophylaxis of respiratory disorders.

20. Use of the pharmaceutical composition according to claim 17 in the manufacture of a medicament for the treatment and/or prophylaxis of asthma or COPD.